Suche
Mein Konto
Barclays analysis: Bayer shares with new insights
Bayer shares: Barclays Capital awards "Equal Weight" for April 15, 2024. Find out the latest analyzes and ratings for Bayer shares here. Exclusively on finanzen.net!
Barclays analysis: Bayer shares with new insights
Barclays Capital has conducted a thorough analysis of Bayer shares and has maintained Bayer's rating at Equal Weight. The price target was set at 28 euros. Analyst Emily Field made minor adjustments to her valuation model before the pharmaceutical and agrochemical company's quarterly figures. These adjustments resulted in their 2024 earnings guidance (EPS) now being at the lower end of the company's target range. Bayer shares fell 0.9 percent to EUR 26.73 in the XETRA session. Nevertheless, there is an upside potential of 4.77 percent compared to the current price target. During trading to date, 2,211,166 Bayer shares have been offered for purchase or sale via XETRA. The share recorded a decline of 20.5 percent for the year 2024. Bayer is expected to present financial results for Q1 2024 on May 14, 2024.